|
|
Determination of content and microscopical indentification of Mongolian medicine Ganluyangxin Pills |
BAO Shunru NA Rentuya WU Yunsuode GAO Lei HAN Tana#br# |
Inner Mongolian Key Laboratory for Standard Research of the Chinese and Mongolian Medicine, Inner Mongolian Institute for Drug Control, Inner Mongolia Autonomous Region, Hohhot 010010, China |
|
|
Abstract Objective To establish a method for the determination and microscopic identification of crocin-Ⅰ and crocin-Ⅱ in Ganluyangxin Pills. Methods The content of crocin-Ⅰ and crocin-Ⅱ in Stigma Croci was determined by high performance liquid chromatography. The column was Waters XBridge C18 (250 mm×4.6 mm, 5 μm), the mobile phase was methanol-water(45∶55), the detection wavelength was 440 nm, the flow rate was 1.0 ml/min, and the column temperature was 30℃. Microscopic identification method was used to study microscopic characteristics of Ganluyangxin Pills. Results Crocin-Ⅰ and crocin-Ⅱ showed good linear relationships within the rage of 5.184-51.837, 2.015-20.154 μg/ml (r = 1.000 0), whose average recovery were 102.32% and 102.40%, the RSD was 1.45% and 1.47%, respectively. Unique characteristics in Spora Lygodii, Fructus Hippophae, Semen Descurainiae, Radix Astragali seu Hedysari, Crab, Mallow flos, Croci stigma L., Ramulus syringae were screened out as microscopic identification basis of Ganluyangxin Pills. Conclusion The method is scientific, reasonable and accurate, and can be used for the quality control of the Ganluyangxin Pills.
|
|
|
|
|
[1] 乔龙巴特·巴德玛阿拉.脉泻剂“甘露养心丸”对慢性心力衰竭模型大鼠心功能及BNP的影响研究[D].呼和浩特:内蒙古医科大学,2019.
[2] 渟海子.蒙医脉泻剂《甘露养心丸》对慢性心力衰竭NT-proBNP和LVEF影响研究[D].呼和浩特:内蒙古医科大学,2020.
[3] 纳顺达来.一种治疗冠心病的蒙药:中国,CN11164362 3A[P].2020.
[4] 国家药典委员会.中华人民共和国药典[S].一部.北京:中国医药科技出版社,2020:134.
[5] 袁娟丽,刘明智,张钰祺.HPLC法测定红羚清散中西红花苷-Ⅰ和西红花苷-Ⅱ的含量[J].江西中医药,2018,49(3):71-73.
[6] 徐鸿,周洋,孙磊.一测多评法测定通滞苏润江胶囊中西红花苷-Ⅰ、西红花苷-Ⅱ的含量[J].中国药品标准,2020, 21(5):440-446.
[7] 胡双,孙文静,徐双双,等.不同产地不同年份西红花含量的HPLC法测定[J].时珍国医国药,2021,32(8):1974-1977.
[8] 王萌萌,徐步斌,周斌,等.HPLC法测定西红花不同部位中西红花苷-Ⅰ和苷-Ⅱ[J].中成药,2019,41(5):1102-1105.
[9] 徐国钧.中药粉末显微鉴别[M].北京:人民卫生出版社,1986:146,334,384,568.
[10] 中华人民共和国卫生部药典委员会.卫生部药品标准蒙药分册[S].1998:4.
[11] 雷蕾,谭鹏,文永盛,等.沙棘与2种易混淆品的鉴别[J].中成药,2021,43(7):1955-1959.
[12] 林晓春,李旭桂,刘萌,等.复方半枝莲胶囊中人参、黄芪的显微鉴别和限量检查[J].海峡药学,2021,33(1):80-82.
[13] 刘灿黄,何清彦,吴胜男,等.前列回春胶囊的显微鉴别研究[J].中南药学,2020,18(10):1702-1705.
[14] 张小冬,刘颖,张军生.黄芪及其伪品的鉴别比较[J].农业科技与装备,2018(1):52-53,56.
[15] 刘波,田晖,沙妙清,等.中药西红花的真伪鉴别研究[J].绿色科技,2019(9):132-134.
[16] 周宝玉,虞文妹.西红花与常见伪劣品鉴别[J].实用中医药杂志,2016,32(7):743-744.
[17] 焦兴苹,范莹莹,才毛,等.藏药洁白丸(胶囊)质量标准提高研究[J].西部中医药,2020,33(7):69-73.
[18] 黄建成,郭世超,刘璞娟,等.西红花苷对大鼠缺血缺氧心肌损伤的保护作用及其机制[J].吉林大学学报(医学版),2021,47(1):102-109.
[19] 朱安运,邓亮,孙琳,等.西红花苷保护心血管疾病药理研究进展[J].中华中医药学刊,2018,36(2):336-340.
[20] 韩宇,谢国勇,李冉,等.西红花苷药理活性的研究进展[J].现代药物与临床,2017,32(9):1806-1814.
[21] Abedimanesh N,Motlagh B,Abedimanesh S,et al. Effects of crocin and saffron aqueous extract on gene expression of SIRT1,AMPK,LOX1,NF-κB,and MCP-1 in patients with coronary artery disease:A randomized placebo-controlled clinical trial [J]. Phytother Res,2020, 34(5):1114-1122.
[22] 楚溪,刘涛,韩雪,等.西红花的化学成分和心血管药理作用的研究概况[J].广州化工,2016,44(18):30-32.
[23] 侯莉,于颖,丁力.西红花苷通过C/EBP-β/PGC-1α/UCP3途径对缺血缺氧损伤心肌的保护作用[J].中国动脉硬化杂志,2019,27(6):481-488.
[24] 孙杰,张玉凤,程汉鹏.不同产地藏红花质量比较研究[C].中国药学会第四届药物检测质量管理学术研讨会资料汇编,2017:303-305.
[25] 任红,姚建标,金辉辉,等.不同年份、不同产地西红花药材的质量研究[J].中国现代应用药学,2016,33(11):1405-1408.
[26] Zhang AL,Shen YW,Cen MP,et al. Polysaccharide and crocin contents, and antioxidant activity of saffron from different origins [J]. Ind Crops Prod,2019,133:111-117. |
|
|
|